by
David Oslin, MD
;
Laura Wray, PhD
Seminar date: 12/10/2018
Description: Despite growing general interest in pharmacogenetics (PGx)—an area of clinical medicine aimed at understanding how genes affect individual responses to treatment—there is currently a lack of sufficient scientific study of its applications in psychiatry. The Veterans Health Administration (VHA) is under increasing pressure to implement a PGx testing program for mental health care, particularly in the treatment of depression. This presentation will summarize the PRIME Care (PRecision medicine In MEntal health Care) study, a large health services RCT led by David Oslin, MD, VISN 4 MIRECC director, that is investigating the effectiveness of providing PGx testing on antidepressant prescribing. The project incorporates implementation science methodology, which will be described by Laura Wray, PhD, Center for Integrated Healthcare (CIH) director, to support the trial and to prepare for rapid implementation if the intervention proves to be effective. Intended Audience: anyone interested in how VA is evaluating and preparing for future use of pharmacogenetics would be interested including researchers, providers, and policy makers.
DOWNLOAD: PDF handout | Audio only (mp3) | transcript
